Abstract will be presented at the 2019 American Thoracic Society
(ATS) International Conference in Dallas
FT. WORTH, Texas–(BUSINESS WIRE)–NanOlogy
LLC, a clinical-stage oncology company, announced today that its
abstract showing encouraging therapeutic effects from a preclinical
pharmacology study on inhaled NanoPac® (submicron particle
paclitaxel) for treatment of lung cancer has been accepted for
presentation at the 2019
American Thoracic Society International Conference.
The abstract, entitled Enhanced Tumor Regression and Immune Cell
Infiltration by Inhaled Submicron Particle Paclitaxel in an Orthotopic
Athymic Nude Rat Model of Non-Small Cell Lung Cancer (NSCLC), will
be presented at the conference on May 20th, 1 PM to 4 PM,
during the Oncogenic Mutations, Metastases, and Novel Therapeutics
poster session at the Kay Bailey Hutchison Convention Center in Dallas.
Previously, NanOlogy conducted a pharmacokinetic study examining
retention of NanoPac in healthy rat lung tissue following a single
inhalation via nose-only exposure chamber. Data showed measurable
amounts of drug in lung tissue 14-days post exposure, with treated lungs
microscopically indistinguishable from normal lung tissue. A preclinical
proof-of-concept study was then conducted to examine the therapeutic
effect of inhaled NanoPac in an orthotopic athymic nude rat model of
NSCLC. An abstract
of that study was presented at the 2018 ASCO Annual Meeting showing
inhaled NanoPac achieved a significant decrease in primitive tumor cell
population as well as significant tumor reduction.
The ATS abstract presents follow-on immunohistochemical analysis of lung
tissue from the proof-of concept study, which showed NanoPac-treated
animals had greater incidence and degree of tumor regression, immune
cell infiltration, and tertiary lymphoid structures compared to
untreated controls and intravenously administered nab-paclitaxel.
Describing the antitumoral immune response, Gere diZerega, MD, VP of
Medical Affairs, observed, “Immunohistochemical analysis showed the
immune cell infiltrates appeared to facilitate destruction of tumor and
its conversion into small fibrin deposits.”
NanOlogy is finalizing preclinical work of inhaled NanoPac in
preparation for an investigational new drug (IND) submission to the US
FDA in mid-2019 to allow for clinical trials in NSCLC.
During the conference, NanOlogy has also been selected to participate in
the International Society for Aerosols in Medicine/ATS Pre-Conference
session on “Current Practice and Future Developments in Aerosol
Medicine.” The session will be held on Saturday, May 18, from 1 PM to 4
PM at the Omni Dallas Hotel Trinity Ballroom 5-7 (Level 3).
Lung cancer is by far the leading cause of cancer death in the United
States according to the American Cancer Society with more than 143,000
deaths projected this year. More people die of lung cancer annually than
breast, prostate, and colon cancers combined.
In addition to lung cancer, NanOlogy clinical
programs are advancing in genitourinary gastrointestinal,
peritoneal, lung, and dermal cancers.
The NanOlogy submicron particle technology platform is based on a
proprietary production process that reduces the size of taxane API
crystals by up to 400 times into stable submicron particles of pure drug
with exponentially increased surface area and unique geometry. The
characteristics of the particles have recently been granted a
composition of matter patent (US
9,814,685) valid in the US until 2036.
About NanOlogy
NanOlogy, LLC (www.nanology.us)
is a private clinical stage oncology company formed in 2015 to finance
and clinically develop a patented submicron particle technology platform
for local, sustained delivery of therapeutic agents aimed at increasing
their value in the treatment of cancer and related conditions.
Disclaimers
This announcement contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended, including
statements about our product development, business, and other
activities. Such statements are subject to the risks and uncertainties
inherent in any pharmaceutical development program which may cause
actual results to differ materially due to developmental, clinical
trial, regulatory, market, competitive, technological, or other factors.
All forward-looking statements are made as of the date of this
announcement and the company disclaims any intent or obligation to
update these statements. NanOlogy investigational drugs have not been
proven to be safe and effective as required by U.S. FDA and have not
been approved by FDA or any other jurisdiction for commercial
distribution.
Contacts
Dan Eramian
Opus Biotech Communications
danieleramian@comcast.net
425-306-8716
Charles Craig
Opus Biotech Communications
charles.s.craig@gmail.com
404-245-0591